Cited by 133Diabetes Treatment and ManagementPharmaceutical Economics and PolicyDiabetes Management and Research

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages

Open access

Whitley, Heather P., Trujillo, Jennifer M., Neumiller, Joshua J.·2023·Clinical Diabetes

Open this paper in CoChat — free account Open PDF

Abstract

Unexpected drug shortages of the long-acting glucagon-like peptide-1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide emerged in late 2022 and have persisted through the first quarter of 2023 (1). The drug shortage has not affected product doses equally; some doses are more widely available than others (2). For the purposes of this article, we will consider the dual GLP-1/GIP receptor agonist tirzepatide to be included when referring to GLP-1 receptor agonist product shortages. These shortages predominately occurred because of an unexpected increase in demand for GLP-1 receptor agonists without adequate adjustment in production (3). The inadequate supply has created new access barriers for patients previously using or wishing to initiate these products for glycemic management, weight loss, and/or cardiovascular risk reduction. Thus, strategies to mitigate this disruption to patient care are needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/cd23-0023

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“Table 2 summarizes available recommendations and information to guide dose selection when resuming a GLP-1 receptor agonist after a more prolonged lapse in therapy (20,21).”
Background
Patient Medication Adherence: Measures in Daily Practice
Jimmy, B., & Jose, J. (2011) · Oman Medical Journal · doi:10.5001/omj.2011.38 · Cited by 956
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851
Drug Shortage: Causes, Impact, and Mitigation Strategies
Shukar, S., Zahoor, F., Hayat, K., Saeed, A., Gillani, A., Omer, S., Hu, S.-C., Babar, Z., Fang, Y., & Yang, C.-J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.693426 · Cited by 301
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Self-citation
GLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282
Self-citation
Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
Frias, J. P., Bonora, E., Nevarez Ruiz, L., Li, Y. G., Yu, Z., Milicevic, Z., Malik, R., Bethel, M. A., & Cox, D. A. (2021) · Diabetes Care · doi:10.2337/dc20-1473 · Cited by 199
Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
Frías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00174-1 · Cited by 188
The drug shortage crisis in the United States: causes, impact, and management strategies.
Ventola, C. L. (2011) · PubMed · Cited by 154
Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74

Flagged first, then by citations

Show all 18 references

Research works printed but not linked: 1

Beba, 2022, PCDS consensus statement: a strategy for managing the supply shortage of the GLP-1 RAs Ozempic and Trulicity, Diabetes & Primary Care, 24, 147

Sorted by citations

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Bajaj, M., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s009 · Cited by 728
Self-citation
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity
Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Goodwin Cartwright, B., Baker, C., Gluckman, T. J., Stucky, N., & Emanuel, E. J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.57349 · Cited by 374
Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity
Rodriguez, P. J., Goodwin Cartwright, B. M., Gratzl, S., Brar, R., Baker, C., Gluckman, T. J., & Stucky, N. L. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.2525 · Cited by 334
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Self-citation
The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis
Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025) · Obesity Reviews · doi:10.1111/obr.13929 · Cited by 111
GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach
Arillotta, D., Floresta, G., Guirguis, A., Corkery, J. M., Catalani, V., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Brain Sciences · doi:10.3390/brainsci13111503 · Cited by 104
Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis
Yeo, Y. H., Rezaie, A., Hsieh, T. Y.-J., Hu, X., Gaddam, S., Ma, K. S.-K., Gastrointestinal Motility and Metabolic Pharmacoepidemiology Group, Mohamed, G., Lee, G. Y., Huang, P.-C., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0019 · Cited by 90
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Giorgi, R. D., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A., Koychev, I. G., Upthegrove, R., Solmi, M., McCutcheon, R. A., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 92
Longitudinal Analysis of Obesity Drug Use and Public Awareness
Berning, P., Adhikari, R., Schroer, A. E., Jelwan, Y. A., Razavi, A. C., Blaha, M. J., & Dzaye, O. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.57232 · Cited by 78
GLP-1 agonists: A review for emergency clinicians
Long, B., Pelletier, J., Koyfman, A., & Bridwell, R. E. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.01.010 · Cited by 67
2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health
Gilbert, O., Gulati, M., Gluckman, T. J., Kittleson, M. M., Rikhi, R., Saseen, J. J., & Tchang, B. G. (2025) · JACC · doi:10.1016/j.jacc.2025.05.024 · Cited by 65
Compounded GLP-1 and dual gip/GLP-1 receptor agonists: a statement from the American Diabetes Association
Neumiller, J. J., Bajaj, M., Bannuru, R. R., McCoy, R. G., Pekas, E. J., Segal, A. R., & ElSayed, N. A. (2025) · Diabetes Care · doi:10.2337/dci24-0091 · Cited by 49
Self-citation
G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials
Beavers, K. M., Cortes, T. M., Foy, C. M., Dinkla, L., Reyes San Martin, F., Ard, J. D., Serra, M. C., & Beavers, D. P. (2025) · Obesity · doi:10.1002/oby.24172 · Cited by 41
Perioperative Management of Patients Taking Glucagon-like Peptide-1 Receptor Agonists: Applying Evidence to Clinical Practice
Oprea, A. D., Umpierrez, G. E., Sweitzer, B., & Hepner, D. L. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005204 · Cited by 42
MetALD: Does it require a different therapeutic option?
Marek, G. W., & Malhi, H. (2024) · Hepatology · doi:10.1097/hep.0000000000000935 · Cited by 41
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Giorgi, R. D., Ghenciulescu, A., Yotter, C. N., Taquet, M., & Koychev, I. G. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-335593 · Cited by 40
Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study
Ashraf, A. R., Mackey, T. K., Vida, R. G., Kulcsár, G., Schmidt, J., Balázs, O., Domián, B. M., Li, J., Csákó, I., & Fittler, A. (2024) · Journal of Medical Internet Research · doi:10.2196/65440 · Cited by 32
Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty
Maselli, D. B., Lee, D., Bi, D., Jirapinyo, P., Thompson, C. C., Donnangelo, L. L., & McGowan, C. E. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07278-2 · Cited by 28
Real-world Evidence on Oral Semaglutide for the Management of Type 2 Diabetes. A Narrative Review for Clinical Practice
Marassi, M., & Fadini, G. P. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.11.005 · Cited by 27
Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States
Ostrominski, J. W., Ortega-Montiel, J., Tesfaye, H., ALIX, C., DiCesare, E., CROMER, S. J., Wexler, D. J., Paik, J. M., & Patorno, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02870 · Cited by 28
Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management
Powell, J., & Taylor, J. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.12.014 · Cited by 25
Prescriptions for Obesity Medications Among Adolescents Aged 12–17 Years with Obesity — United States, 2018–2023
Kompaniyets, L., Pierce, S. L., Porter, R. M., Autrey, K., Chua, K., Belay, B., Blanck, H. M., & Goodman, A. B. (2025) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7420a1 · Cited by 23
Monitoring Report: GLP-1 RA Prescribing Trends - September 2024 DataPreprint
Gratzl, S., Rodriguez, P. J., Cartwright, B. M. G., Baker, C., & Stucky, N. L. (2024) · medRxiv · doi:10.1101/2024.01.18.24301500 · Cited by 22
Quality of information and social norms in Spanish-speaking TikTok videos as levers of commercial practices: The case of semaglutide
Campos, P. A., Alfaro–Ponce, B., Pérez, B. M. R., Bernal-Serrano, D., Contreras-Loya, D., & Wirtz, V. J. (2024) · Social Science & Medicine · doi:10.1016/j.socscimed.2024.117646 · Cited by 22
Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017–2022
Gaw, C. E., Hays, H. L., Kemp, C. A., Kistamgari, S., Spiller, H. A., Rine, N. I., Rhodes, A. L., Zhu, M., & Smith, G. A. (2024) · Journal of Medical Toxicology · doi:10.1007/s13181-024-00999-x · Cited by 19
Glucagon-Like Peptide-1 Agonists and General Anesthesia: Perioperative Considerations and the Utility of Gastric Ultrasound
Willson, C. M., Patel, L., Middleton, P., & Desai, M. M. (2024) · Cureus · doi:10.7759/cureus.58042 · Cited by 17
Verapamil chronicles: advances from cardiovascular to pancreatic β-cell protection
Arefanian, H., Koti, L., Sindhu, S. T. A. K., Ahmad, R., Madhoun, A. S. A., & Al‐Mulla, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1322148 · Cited by 16
The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review
McGill, J. B., Hirsch, I. B., Parkin, C. G., Aleppo, G., Levy, C. J., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01569-8 · Cited by 24
Barriers to Care for Pediatric Patients with Obesity
Bodepudi, S., Hinds, M., Northam, K. A., Reilly-Harrington, N. A., & Stanford, F. C. (2024) · Life · doi:10.3390/life14070884 · Cited by 20
Monitoring Report: GLP-1 RA Prescribing Trends - September 2026 DataPreprint
Gratzl, S., Gilbert, K. M., Holler, E., Vachon, M. S., Masters, N. B., Wallen, Z. D., & Cartwright, B. M. G. (2025) · medRxiv · doi:10.1101/2025.03.06.25323524 · Cited by 15
One Size Does Not Fit All: Understanding Microdosing Semaglutide for Diabetes in Multidose Pens
Komé, A. M., Chandran, M. M., Lopez, S. S. T., Buse, J. B., & Klein, K. R. (2025) · Diabetes Care · doi:10.2337/dc24-2575 · Cited by 14
Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes
Zhang, D., Gencerliler, N., Mukhopadhyay, A., Blecker, S., Grams, M. E., Wright, D. R., Wang, V. H.-C., Rajan, A., Butt, E., Shin, J.-I., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2746 · Cited by 14
Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care
Morieri, M. L., Candido, R., Frontoni, S., Disoteo, O., Solini, A., Fadini, G. P., for the PIONEERING EXPERIENCE study group, Bellanti, F., Caprio, M., Cutolo, M., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01490-6 · Cited by 14
Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists
Spinelli, K. J., Oakes, A. H., Chiu, S., Imboden, M. T., Miller, A. B., Jain, S., & Gluckman, T. J. (2025) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2025.100100 · Cited by 15
Current Perspectives on GLP-1 Agonists in Contemporary Clinical Practice from Science and Mechanistic Foundations To Optimal Translation
Abu-Nejim, H., & Becker, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01350-7 · Cited by 15
Japan initiates market authorization of weight‐loss drug semaglutide under universal health coverage, but with stringent prescription restrictions
Hakariya, H., Ohnishi, M., & Tanimoto, T. E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15638 · Cited by 12
The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review
Kaye, A. D., Sala, K. R., Abbott, B. M., Dicke, A., Johnson, L. D., Wilson, P. A., Amarasinghe, S. N., Singh, N., Ahmadzadeh, S., Kaye, A. M., et al. (2024) · Cureus · doi:10.7759/cureus.67232 · Cited by 12
Liraglutide vs Semaglutide vs Dulaglutide in Veterans With Type 2 Diabetes
Derington, C. G., Sarwal, A., Wei, G., Hartsell, S. E., Throolin, M. J., Singh, R., Nevers, M. R., Zhang, C., Katkam, N., Takyi, A., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.37297 · Cited by 13
Legal, safety, and practical considerations of compounded injectable semaglutide
Spitery, A., Elder, M. J., Farhat, N., Mohammad, I., & Lobkovich, A. M. (2024) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1999 · Cited by 11
An exploratory analysis of glucagon‐like peptide‐1 ( GLP ‐1) agonists and biosimilars: A literature review
Wen, J., Razick, A. A., How-Volkman, C., Bernstein, E., Nadora, D., Truong, A., Razick, D., Akhtar, M., Karabala, M., & Frezza, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16110 · Cited by 16
Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus
Alqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Addressing the Shortage of GLP-1 RA and Dual GIP/GLP-1 RA-Based Therapies—A Systematic Review
Altabas, V., Orlović, Z., & Baretić, M. (2025) · Diabetology · doi:10.3390/diabetology6060052 · Cited by 10
The impact of GLP-1 receptor agonist shortages on glycaemic Control: Findings from an Australian specialist diabetes clinic
Nanayakkara, N., Huang, M. L. H., Jenkins, A. J., & Cohen, N. D. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111740 · Cited by 9
Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 21
Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments
Pryke, L. A., Koethe, J. R., & Bailin, S. S. (2026) · Current HIV/AIDS Reports · doi:10.1007/s11904-026-00776-1 · Cited by 9
A Brain Reward Circuit Inhibited By Next-Generation Weight Loss DrugsPreprint
Godschall, E., Güngül, T. B., Sajonia, I. R., Buyukaksakal, A. K., Li, O. D.-A., Ogilvie, S., Keeler, A. B., Tian, G., Koita, O., Shi, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.12.628169 · Cited by 8
NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2024) · Peptides · doi:10.1016/j.peptides.2024.171256 · Cited by 8
Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?
Lafferty, R. A., Flatt, P. R., Gault, V. A., & Irwin, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0339 · Cited by 8
Implementation and evaluation of a pharmacist-led glucagon-like peptide-1 receptor agonist titration service in two primary care clinics
Miller, K., Carson, E., Boothe, K., & Brown, B. (2025) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2025.102385 · Cited by 7
Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024
Alibilli, A. S., Jain, V., Mane, H., Yue, X., Ratzki‐Leewing, A. A., Merchant, J. S., Criss, S., Nguyen, Q. C., McCoy, R. G., & Nguyen, T. T. X. (2025) · JMIR Infodemiology · doi:10.2196/73619 · Cited by 8
Trends in first-line glucose-lowering medication use among US adults with type 2 diabetes from 2019 to 2023
Do, D., Lee, T., Peasah, S. K., Inneh, A., Patel, U. B., & Good, C. B. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.5.520 · Cited by 7
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies
Palani, A., Patel, S., Patel, S., Srivastava, S., Patel, J., Salehin, S., Birnbaum, Y., & Allencherril, J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07744-8 · Cited by 7
Insulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes
Saeed, Z. I., Aktürk, H. K., Aleppo, G., Kruger, D. F., Levy, C. J., Mader, J. K., Sherr, J. L., & Shah, V. N. (2024) · Clinical Diabetes · doi:10.2337/cd24-0067 · Cited by 7
Shifting the Scales: Tirzepatide's Breakthrough in Obesity Management
Sallam, M., Snygg, J., Allam, D., & Kassem, R. (2024) · Cureus · doi:10.7759/cureus.60545 · Cited by 6
Use of glucagon-like peptide 1 (GLP-1) agonists among exercisers and recreational athletes and associated mental health symptoms
Martin, D., Hawkins, R. M., Gee, T., Turnock, L. A., & Lazuras, L. (2025) · Performance Enhancement & Health · doi:10.1016/j.peh.2025.100353 · Cited by 6
Real‐world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre‐diabetes
Coon, S. A., White, R. T., Pagnozzi, D., & Cowart, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16349 · Cited by 5
Evaluating the use of adjuvant and neoadjuvant terminology in bariatric surgery: a scoping review
Sher, T., McGee, M. Y., DuCoin, C. G., Sujka, J. A., & Docimo, S. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.03.009 · Cited by 6
Navigating Glucagon-Like Peptide Receptor Agonist Reinitiation Amid Access Barriers: An Adverse Drug Event Case Report
Denny, O., Baron, J. I., & Albanese, N. P. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241256775 · Cited by 5
Discontinuation and Reinitiation of GLP-1 Receptor Agonists Among US Adults with Overweight or ObesityPreprint
Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Cartwright, B. M. G., Baker, C., Gluckman, T. J., Stucky, N. L., & Emanuel, E. J. (2024) · medRxiv · doi:10.1101/2024.07.26.24311058 · Cited by 5
Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists
Marshall, L. Z., Gleason, P. P., Friedlander, N., Farley, J., & Urick, B. Y. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.3.281 · Cited by 6
Navigating Cost and Access Barriers for Medications in the Treatment of Obesity: A Guide for Patients and Primary Care Clinicians
Herges, J. R., Neumiller, J. J., & McCoy, R. G. (2025) · Clinical Diabetes · doi:10.2337/cd24-0115 · Cited by 5
Self-citation
How Glucagon-Like Peptide-1 Medications Are Depicted in Instagram Posts Regarding Women’s Health, Nontraditional Access, and Barriers to Access: Content Analysis
Bloom, B. E., Bragg, M. A., Jay, M. R., Harel, D., Cline, C., Crowe, M., Montoya, A., Muthuramalingam, S., Santana, R., & Albert, S. L. (2025) · Journal of Medical Internet Research · doi:10.2196/66400 · Cited by 5
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
Erlandson, K. M., Kitch, D. W., Kantor, A., Belaunzarán-Zamudio, P. F., Brown, T. T., Fichtenbaum, C. J., Heath, S. L., Sattler, F. R., & Lake, J. E. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf652 · Cited by 5
Public Health Responsibilities in the Era of GLP-1 Receptor Agonists
Wang, G., Rahim, E., Bari, S., Haque, H., Rahim, F. O., & Palakodeti, S. (2024) · Journal of Public Health Management and Practice · doi:10.1097/phh.0000000000002039 · Cited by 7
Real‐world observations of using compounded GLP ‐1 ± GIP agonists within a clinical pharmacist‐managed cardiometabolic clinic
Finks, S. W., Benavides, D., Martin, A. G., & Carmon, A. S. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.2071 · Cited by 4
Insulin requirements after switching from GLP ‐1 receptor agonist to dual GIP / GLP ‐1 receptor agonist in patients with type 2 diabetes mellitus
Lahey, A. M., Duprey, K. S., Montague, R. C., Schadler, A. D., & Naseman, K. (2025) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70009 · Cited by 5
First-Time Prescribing of GLP-1 Receptor Agonists from 2018-2023: A Descriptive AnalysisPreprint
Rodriguez, P. J., Gratzl, S., Cartwright, B. M. G., Brar, R., Gluckman, T. J., & Stucky, N. L. (2023) · medRxiv · doi:10.1101/2023.08.22.23294277 · Cited by 4
Advancing Person-Centered Care in the New Era of Obesity Treatment
Schumacher, L. M., Brocq, S. L., Wharton, S., Fox, C. K., Schur, E. A., Sumithran, P., & Ard, J. D. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09742-w · Cited by 4
SGLT2 Inhibitor and GLP‐1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross‐Sectional Study
Müller, F., Bouthillier, M. J., Alshaarawy, O., Azhary, H., & Holman, H. T. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6656982 · Cited by 3
Healthcare Resource Utilisation and Cost of Obesity and Related Complications in the United States: A Systematic Literature Review
Almandoz, J. P., Ard, J. D., Gazda, C., & Edwards-Hampton, S. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70602 · Cited by 3
Trends in GLP-1 Receptor Agonist and SGLT2-Inhibitor Utilization and Expenditure Between 2017–2023: Demographic, Income, and Insurance Associations
Jacobs, M., Fang, Q., & Ellis, C. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-026-10408-4 · Cited by 3
Evolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3
Measuring the Quality and Safety of Upper Endoscopy in Patients Taking Glucagon-like Peptide 1 Receptor Agonists
Bansal, R., Khan, R., & Grover, S. C. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.04.001 · Cited by 3
Setting Expectations When Prescribing Medication for the Treatment of Patients With Obesity
Fitch, A. (2025) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2025.100621 · Cited by 2
Managing glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in clinical practice
Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 3
The Pharmacist's Role in the Use of Incretin‐Based Therapies for Weight Management: An Opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
Widespread exposure to GLP-1RAs and weight loss–related discourse: Considering potential public health implications
Côté, M., Salas, X. R., Carrière, K., & Alberga, A. S. (2026) · Canadian Journal of Public Health · doi:10.17269/s41997-026-01197-8 · Cited by 2
Navigating uncharted waters: long-term implications of GLP-1 agonist use
Sher, T., & Sujka, J. A. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.01.005 · Cited by 2
Characterization of Interchanging Incretin Analogs in Clinical Practice: A Descriptive Report
Hvisdas, C., Goode, N., Kim, D. H., Silvey, M. J., & Flood, J. J. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.117 · Cited by 2
Missed Doses, Missed Opportunities: Readmission Due to GLP-1RA Interruption Inspires Algorithms to Improve Reinitiation of Therapy at Discharge
Michelet, A., Mowla, M., Amo-Brown, B. A., Rodriguez, N., & Cavaretta, M. J. (2025) · Hospital Pharmacy · doi:10.1177/00185787251372054 · Cited by 2
Differences in GLP-1 RA medication adherence across place-based variables in patients with diabetes living in Wisconsin
Gavin, K. L., Amjad, R., Makris, V., & Neuner, J. M. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.12.1311 · Cited by 2
The Global Shortage of Glucagon-Like Peptide-1 Receptor Agonists
Yi, D. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.1.1 · Cited by 1
Resmetirom: New Drug, Familiar Challenges?
Bodnar, T. W., & McCurdy, H. M. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.06.001 · Cited by 1
Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial
Haff, N., Horn, D. M., Bhatkhande, G., Sung, M., Colling, C., Wood, W., Robertson, T., Gaposchkin, D. P., Simmons, L. H., Yang, J., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.02.007 · Cited by 2
Tipping the Scales: Strategies to Improve Anti‐Obesity Medication Access and Affordability
Komé, A. M., Boykin, A. R., Johnson-Jennings, A., & Coviello, A. D. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70118 · Cited by 1
An Integrated Interprofessional Continuing Medical Education and Quality Improvement Initiative to Address Cardiovascular and Renal Risk in Patients with Type 2 Diabetes in Community-Based Primary Care Practices
Lazure, P., Pantalone, K. M., FRAMPTON, B. D., Kawczak, S., Murray, S., Rao, P. P. R., & Makin, V. (2025) · Journal of CME · doi:10.1080/28338073.2025.2571295 · Cited by 2
Weight‐Reduction and Safety Profile of Once‐Weekly Non‐Comparable Biotherapeutic Subcutaneous Semaglutide Among People With Obesity: A Real‐World Retrospective Study
Hasan, M. R., Shil, K. K., & Morshed, M. S. (2026) · Health Science Reports · doi:10.1002/hsr2.71745 · Cited by 1
Developing a Weight Management and Metabolic Health Program to support patient-centred, effective, and efficient treatment for veterans with overweight or obesity: protocol for a quality improvement programme
Malhotra, D., Henderson, J., Turner, C. D., O’Rourke, R. W., McAuley, K. B., Heisler, M., Otto, M. G., Thomason, C., O’Neill, J. L., Freeman, K., et al. (2026) · Primary Health Care Research & Development · doi:10.1017/s1463423625100650 · Cited by 1
Use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with ischaemic heart disease and type 2 diabetes in Swedish primary care: a cross-sectional analysis of regional primary care registry data (QregPV)
Andersson, T., Bager, J., Hellgren, M. I., Åberg, M., & Mourtzinis, G. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-110395 · Cited by 1
Challenges in the management of obesity
Smith, B. L., May, A., Lalani, F., Hasham, S., & Presnell, A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.023 · Cited by 4
Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus
Kugathasan, L., Katz, A., Muskiet, M. H. A., Sridhar, V. S., Scott, J., Yi, T. W., & Cherney, D. Z. I. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106547 · Cited by 1
Facelift Demand Among Patients Using Glucagon-Like Peptide-1 Receptor Agonists: The Impact of Weight Loss-Associated Facial Changes
Harsinay, A., Rosi‐Schumacher, M., Favre, N., & Sherris, D. A. (2026) · Facial Plastic Surgery & Aesthetic Medicine · doi:10.1177/26893614261448298 · Cited by 1
Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland
Łupina, K., Dziewierz, A., Janczura, J., & Siudak, Z. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02709-1 · Cited by 1
Clinical Guidance on the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in Adults with Type 1 Diabetes
Saeed, Z. I., & Shah, V. N. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.006 · Cited by 1
The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon‐Like Peptide‐1‐Based Therapies
Overgaard, R. V., Agersø, H., Hollensen, C., Rathor, N., & Bomberg, E. M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71030 · Cited by 1

Authors: Whitley, H. P., Trujillo, J. M., & Neumiller, J. J.
Affiliations: Baptist Health System (US)
University of Colorado Anschutz (US)
Washington State University Spokane (US)
Corresponding author: Trujillo, Jennifer M.
ORCID: Whitley, Heather P.
Trujillo, Jennifer M.
Neumiller, Joshua J.
Venue: Clinical Diabetes
Publisher: American Diabetes Association
Published: 2023-04-07
Volume: 41
Issue: 3
Pages: 467-473
ISSN: 0891-8929 (ISSN-L)
1945-4953
DOI: 10.2337/cd23-0023
PMC: PMC10338283
OpenAlex: W4362703983
Cited by: 132
References: 18
Citations by year: 2026: 27 · 2025: 58 · 2024: 43 · 2023: 4
FWCI: 27.08
Type: journal article
Language: en
Update notices: correction (2024-08-13)
Open access: bronze
doi.org
Licence: www.diabetesjournals.org/journals/pages/license (vor)
Locations: Clinical Diabetes (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords: drug shortages, GLP-1 receptor agonists, dulaglutide, semaglutide, tirzepatide, GIP/GLP-1 receptor agonist, supply and demand imbalance, glycemic control, weight loss, cardiovascular risk reduction, access to medicines, mitigation measures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks